Skip to main content
ApicHope Pharmaceutical Group Co.,Ltd logo

ApicHope Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 300723 ISIN · CNE1000035J7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,592 across all filing types
Latest filing 2026-05-21 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300723

About ApicHope Pharmaceutical Group Co.,Ltd

https://www.gdyph.com

ApicHope Pharmaceutical Group Co., Ltd. is a comprehensive enterprise dedicated to the research, development, manufacturing, and commercialization of pharmaceutical products. The company maintains a strategic focus on pediatric medicine, offering a diverse portfolio of specialized formulations for children, including treatments for respiratory, digestive, and infectious diseases. In addition to its pediatric leadership, the group develops medications for chronic conditions, cardiovascular health, and the central nervous system. ApicHope operates advanced production bases that integrate the manufacturing of active pharmaceutical ingredients (APIs) with finished dosage forms. Its R&D efforts are centered on clinical demand and innovative drug delivery systems to enhance therapeutic efficacy. The organization utilizes a robust marketing and distribution infrastructure to deliver healthcare solutions across multiple therapeutic categories.

Recent filings

Filing Released Lang Actions
关于全资子公司获得氨基己酸注射液注册证书的公告
Regulatory Filings Classification · 74% confidence The document is a corporate “公告” announcing that the company’s wholly‐owned subsidiary received a drug registration certificate from the National Medical Products Administration. It provides regulatory approval details (certificate number, product specs, approval body) and notes the impact on operations. There are no financial statements, shareholder votes, management changes, or capital transactions. This fits best under a general regulatory announcement that does not fall into any more specific filing category, so it should be classified as a Regulatory Filing (RNS).
2026-05-21 Chinese
北京市中伦（广州）律师事务所关于一品红药业集团股份有限公司2025年度股东会的法律意见书
Regulatory Filings Classification · 75% confidence The document is a legal opinion letter (法律意见书) from Zhong Lun law firm regarding the convocation, procedures and voting at the company’s 2025 annual shareholders meeting. It does not contain primary financial data or constitute a shareholder notice; rather, it is an attestation/certification by lawyers confirming the meeting’s legality. Under the Certification Rule, such officer certifications or legal opinion letters are classified as Regulatory Filings (RNS) rather than as the meeting itself or an annual report.
2026-05-18 Chinese
2025年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled “2025年度股东会决议公告” and details the attendance, individual proposals, and precise vote counts (agree, oppose, abstain) for each resolution at the annual shareholders’ meeting. This corresponds exactly to a Declaration of Voting Results from a general meeting. It is not the full annual report or presentation materials, but a formal announcement of vote outcomes. Therefore, the filing category is DVA.
2026-05-18 Chinese
第四届董事会第十七次会议决议公告
Regulatory Filings Classification · 80% confidence The document is a formal announcement of board of directors’ meeting resolutions (a “董事会决议公告”) filed on the stock exchange, detailing items approved and vote outcomes. It does not itself constitute an annual or interim report, nor an earnings release, proxy statement, or director/shareholder vote declaration. It also does not announce changes in board composition (so not MANG). As a general regulatory filing that doesn’t neatly fit other specific categories, it is best classified as a Regulatory Filing (RNS).
2026-04-23 Chinese
2025年度财务决算报告
Audit Report / Information Classification · 90% confidence The document is titled “2025年度财务决算报告” and immediately presents an auditor’s standard unqualified opinion followed by detailed balance sheet, income statement, and cash flow statement line by line. It does not include broad business narrative, governance, or management discussion sections typical of a full Annual Report (10-K), nor is it a short notice or summary. Instead, it is a standalone audited financial report, matching the definition of an Audit Report/Information (AR).
2026-04-23 Chinese
2025 年度营业收入扣除情况的专项审核报告
Audit Report / Information Classification · 95% confidence The document is titled as a '专项审核报告' (special audit report) concerning the 2025 fiscal year revenue deduction situation of a company. It references an audit conducted by a registered CPA and mentions compliance with specific stock exchange listing rules and auditing standards. The content focuses on the auditor's responsibility and the management's responsibility regarding the revenue deduction statement. The document is relatively short (891 characters) and appears to be a standalone audit or assurance report rather than a full annual report or interim report. It does not contain full financial statements or comprehensive financial performance data but rather a specific audit opinion on a particular financial aspect (revenue deduction). Therefore, it fits best under the category of Audit Report / Information (AR).
2026-04-23 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.